{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:36:34Z","timestamp":1789706194964,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We aimed to validate the prognostic significance of tumor budding (TB) in p16-positive oropharyngeal squamous cell carcinomas (OPSCC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analyzed digitized H&amp;E-stained slides from a multicenter cohort of five large university centers consisting of <jats:italic>n<\/jats:italic>\u2009=\u2009275 cases of p16-positive OPSCC. We evaluated TB along with other histological parameters (morphology, tumor-stroma-ratio, lymphovascular invasion (LVI), perineural invasion) and calculated survival outcomes using both univariate and multivariate analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>TB was identified as an independent prognostic parameter, with TB-high cases showing inferior outcomes in univariate (HR: 3.08, 95%-CI: 1.71\u20135.54) and multivariate analyses (HR: 4.03, 95%-CI: 1.65\u20139.83). Similarly, LVI remained an independent prognostic factor (HR: 3.00, 95%-CI: 1.22\u20137.38). A combined classification including TB and LVI stratified cases into low-, intermediate- and high-risk categories. We could not detect correlations between TB and the number of lymph node metastases or between TB and an extracapsular extension of lymph node metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In addition to LVI, we could identify TB as an independent prognostic factor in p16-positive OPSCC in this multicenter study cohort. Thus, evaluating TB along with LVI in a combined scheme for prognostication might help to establish a more personalized treatment regimen for patients with p16-positive OPSCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-024-02912-3","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T13:55:39Z","timestamp":1732888539000},"page":"212-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas"],"prefix":"10.1038","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8897-5165","authenticated-orcid":false,"given":"Fabian","family":"St\u00f6gbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Lauterbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schmidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-7389","authenticated-orcid":false,"given":"Cosima C.","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-5617","authenticated-orcid":false,"given":"Iordanis","family":"Ourailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-1711","authenticated-orcid":false,"given":"Jochen","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5418-3349","authenticated-orcid":false,"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Iro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoniu-Oreste","family":"Gostian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Jesinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julika","family":"Ribbat-Idel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena-Wilbeth","family":"Sailer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Perner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Ludwig","family":"Bruchhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"L\u00fckewille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane Maria","family":"Stuhlmann-Laeisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-8002","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Mogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-5327","authenticated-orcid":false,"given":"Jan","family":"Budczies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-7922","authenticated-orcid":false,"given":"Melanie","family":"Boxberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2912_CR1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3122\/jabfm.2021.04.200588","volume":"34","author":"JC Nogues","year":"2021","unstructured":"Nogues JC, Fassas S, Mulcahy C, Zapanta PE. Human Papillomavirus-Associated Head and Neck Cancer. J Am Board Fam Med. 2021;34:832\u20137.","journal-title":"J Am Board Fam Med"},{"key":"2912_CR2","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Bai W, Wang B, Wei J, Ji R, et al. Feasibility of Immunohistochemical p16 Staining in the Diagnosis of Human Papillomavirus Infection in Patients With Squamous Cell Carcinoma of the Head and Neck: A Systematic Review and Meta-Analysis. Front Oncol. 2020;10:524928.","journal-title":"Front Oncol"},{"key":"2912_CR3","unstructured":"El-Naggar AK, Chan JKC, Grandis JR, Slootweg PJ. WHO Classification of Head and Neck Tumours. Lyon (France): IARC Who Classification of Tum; 2017. 347."},{"key":"2912_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oraloncology.2016.01.002","volume":"54","author":"PP Sedghizadeh","year":"2016","unstructured":"Sedghizadeh PP, Billington WD, Paxton D, Ebeed R, Mahabady S, Clark GT, et al. Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis. Oral Oncol. 2016;54:15\u201327.","journal-title":"Oral Oncol"},{"key":"2912_CR5","volume":"2014","author":"V Bol","year":"2014","unstructured":"Bol V, Gr\u00e9goire V. Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers. Biomed Res Int. 2014;2014:696028.","journal-title":"Biomed Res Int"},{"key":"2912_CR6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","volume":"34","author":"DI Rosenthal","year":"2016","unstructured":"Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, et al. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016;34:1300\u20138.","journal-title":"J Clin Oncol"},{"key":"2912_CR7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jclinpath-2020-206686","volume":"73","author":"S Rahimi","year":"2020","unstructured":"Rahimi S. HPV-related squamous cell carcinoma of oropharynx: a review. J Clin Pathol. 2020;73:624\u20139.","journal-title":"J Clin Pathol"},{"key":"2912_CR8","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. Hoboken, New Jersey (USA): John Wiley & Sons; 2017. 272 p.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"2912_CR9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas Network.","year":"2015","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576\u201382.","journal-title":"Nature"},{"key":"2912_CR10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.21037\/atm-20-2984","volume":"8","author":"MP Strohl","year":"2020","unstructured":"Strohl MP, Wai KC, Ha PK. De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma-a narrative review. Ann Transl Med. 2020;8:1601.","journal-title":"Ann Transl Med"},{"key":"2912_CR11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.canrad.2021.02.001","volume":"25","author":"I Brook","year":"2021","unstructured":"Brook I. Early side effects of radiation treatment for head and neck cancer. Cancer Radiother. 2021;25:507\u201313.","journal-title":"Cancer Radiother"},{"key":"2912_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105620","volume":"123","author":"P Golusinski","year":"2021","unstructured":"Golusinski P, Corry J, Poorten VV, Simo R, Sj\u00f6gren E, M\u00e4kitie A, et al. De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed? Oral Oncol. 2021;123:105620.","journal-title":"Oral Oncol"},{"key":"2912_CR13","first-page":"4","volume":"8","author":"H Mirghani","year":"2018","unstructured":"Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin Transl Radiat Oncol. 2018;8:4\u201311.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2912_CR14","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1002\/hed.25872","volume":"41","author":"AA M\u00e4kitie","year":"2019","unstructured":"M\u00e4kitie AA, Almangush A, Rodrigo JP, Ferlito A, Leivo I. Hallmarks of cancer: Tumor budding as a sign of invasion and metastasis in head and neck cancer. Head Neck. 2019;41:3712\u20138.","journal-title":"Head Neck"},{"key":"2912_CR15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/jclinpath-2018-205454","volume":"72","author":"M Boxberg","year":"2019","unstructured":"Boxberg M, Bollwein C, J\u00f6hrens K, Kuhn PH, Haller B, Steiger K, et al. Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance. J Clin Pathol. 2019;72:285\u201394.","journal-title":"J Clin Pathol"},{"key":"2912_CR16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41416-019-0719-8","volume":"122","author":"M Jesinghaus","year":"2020","unstructured":"Jesinghaus M, Steiger K, St\u00f6gbauer F, Haller B, Kolk A, Stra\u00dfen U, et al. Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. Br J Cancer. 2020;122:835\u201346.","journal-title":"Br J Cancer"},{"key":"2912_CR17","doi-asserted-by":"publisher","unstructured":"Okuyama K, Suzuki K, Yanamoto S. Relationship between Tumor Budding and Partial Epithelial-Mesenchymal Transition in Head and Neck Cancer. Cancers. 2023;15. Available from: https:\/\/doi.org\/10.3390\/cancers15041111.","DOI":"10.3390\/cancers15041111"},{"key":"2912_CR18","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41416-023-02240-y","volume":"128","author":"F St\u00f6gbauer","year":"2023","unstructured":"St\u00f6gbauer F, Beck S, Ourailidis I, Hess J, Poremba C, Lauterbach M, et al. Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer. Br J Cancer. 2023;128:2295\u2013306.","journal-title":"Br J Cancer"},{"key":"2912_CR19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08222-8","volume":"21","author":"A Almangush","year":"2021","unstructured":"Almangush A, Alabi RO, Troiano G, Coletta RD, Salo T, Pirinen M, et al. Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21:480.","journal-title":"BMC Cancer"},{"key":"2912_CR20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2023.03.010","volume":"136","author":"A Almangush","year":"2023","unstructured":"Almangush A, Jouhi L, Haglund C, Hagstr\u00f6m J, M\u00e4kitie AA, Leivo I. Tumor-stroma ratio is a promising prognostic classifier in oropharyngeal cancer. Hum Pathol. 2023;136:16\u201324.","journal-title":"Hum Pathol"},{"key":"2912_CR21","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.4317\/medoral.24922","volume":"27","author":"EF Morais","year":"2022","unstructured":"Morais EF, Morais HG, Martins HD, Carlan LM, Costa AD, Freitas RD. Prognostic and clinicopathological significance of tumor-stroma ratio in head and neck squamous cell carcinoma: A systematic review. Med Oral Patol Oral Cir Bucal. 2022;27:e301\u20139.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2912_CR22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41416-022-01708-7","volume":"126","author":"A Almangush","year":"2022","unstructured":"Almangush A, Jouhi L, Atula T, Haglund C, M\u00e4kitie AA, Hagstr\u00f6m J, et al. Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. Br J Cancer. 2022;126:1589\u201394.","journal-title":"Br J Cancer"},{"key":"2912_CR23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","volume":"142","author":"JS Lewis Jr","year":"2018","unstructured":"Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018;142:559\u201397.","journal-title":"Arch Pathol Lab Med"},{"key":"2912_CR24","unstructured":"WHO Classification of Tumours Editorial Board. Head and Neck Tumours: Who Classification of Tumours. Lyon (France): World Health Organization; 2024. 836."},{"key":"2912_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41571-020-0422-y","volume":"18","author":"A Lugli","year":"2021","unstructured":"Lugli A, Zlobec I, Berger MD, Kirsch R, Nagtegaal ID. Tumour budding in solid cancers. Nat Rev Clin Oncol. 2021;18:101\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"2912_CR26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017;24:311\u201335.","journal-title":"Adv Anat Pathol"},{"key":"2912_CR27","doi-asserted-by":"crossref","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV, Gy\u0151rffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862.","journal-title":"PLoS One"},{"key":"2912_CR28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hed.26019","volume":"42","author":"T Tham","year":"2020","unstructured":"Tham T, Ahn S, Frank D, Kraus D, Costantino P. Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: National Cancer Database study. Head Neck. 2020;42:434\u201345.","journal-title":"Head Neck"},{"key":"2912_CR29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2015.10.009","volume":"42","author":"P Boscolo-Rizzo","year":"2016","unstructured":"Boscolo-Rizzo P, Pawlita M, Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat Rev. 2016;42:24\u20139.","journal-title":"Cancer Treat Rev"},{"key":"2912_CR30","doi-asserted-by":"crossref","unstructured":"Chen AM. De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: Who, why, what, where, when, how, how much and what next? Radiother Oncol. 2024;8;110373.","DOI":"10.1016\/j.radonc.2024.110373"},{"key":"2912_CR31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","volume":"19","author":"M Lechner","year":"2022","unstructured":"Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022;19:306\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"2912_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.oraloncology.2012.07.015","volume":"49","author":"SH Huang","year":"2013","unstructured":"Huang SH, Perez-Ordonez B, Weinreb I, Hope A, Massey C, Waldron JN, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49:79\u201385.","journal-title":"Oral Oncol"},{"key":"2912_CR33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/modpathol.2017.46","volume":"30","author":"A Lugli","year":"2017","unstructured":"Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299\u2013311.","journal-title":"Mod Pathol"},{"key":"2912_CR34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/his.14822","volume":"82","author":"D Wankhede","year":"2023","unstructured":"Wankhede D, Hofman P, Grover S. Prognostic impact of tumour budding in squamous cell carcinoma of the lung: a systematic review and meta-analysis. Histopathology. 2023;82:521\u201330.","journal-title":"Histopathology"},{"key":"2912_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41416-023-02531-4","volume":"130","author":"A Almangush","year":"2024","unstructured":"Almangush A, M\u00e4kitie AA, Leivo I. Tumour budding in head and neck cancer: what have we learnt and the next steps towards clinical implementation. Br J Cancer. 2024;130:1\u20132.","journal-title":"Br J Cancer"},{"key":"2912_CR36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/hed.27583","volume":"46","author":"E Zanoletti","year":"2024","unstructured":"Zanoletti E, Daloiso A, Nicol\u00e8 L, Cazzador D, Mondello T, Franz L, et al. Tumor budding to investigate local invasion, metastasis, and prognosis of head and neck carcinoma: A systematic review. Head Neck. 2024;46:651\u201371.","journal-title":"Head Neck"},{"key":"2912_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAI.0000000000000966","volume":"30","author":"X Wen","year":"2022","unstructured":"Wen X, Zee SY, Shroyer KR, Bandovic J. Intratumoral Budding and Tumor Microenvironment in Pretreatment Rectal Cancer Biopsies Predict the Response to Neoadjuvant Chemoradiotherapy. Appl Immunohistochem Mol Morphol. 2022;30:1\u20137.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2912_CR38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/bjc.2017.425","volume":"118","author":"A Almangush","year":"2018","unstructured":"Almangush A, Pirinen M, Heikkinen I, M\u00e4kitie AA, Salo T, Leivo I. Tumour budding in oral squamous cell carcinoma: a meta-analysis. Br J Cancer. 2018;118:577\u201386.","journal-title":"Br J Cancer"},{"key":"2912_CR39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12070-021-02981-3","volume":"74","author":"S Gupta","year":"2022","unstructured":"Gupta S, Sreeram S, Pinto AC, Suresh PK, Basavaiah SH. Tumor Budding Assessment with Cytokeratin and Its Significance in Laryngeal Squamous Cell Carcinomas. Indian J Otolaryngol Head Neck Surg. 2022;74:494\u2013500.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"2912_CR40","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/hed.27473","volume":"45","author":"YM Park","year":"2023","unstructured":"Park YM, Lim JY, Koh YW, Choi EC, Kim SH. Surgical margin status and role of adjuvant therapy in human papillomavirus-positive oropharyngeal cancer. Head Neck. 2023;45:2369\u201376.","journal-title":"Head Neck"},{"key":"2912_CR41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JOP.2017.025247","volume":"14","author":"H Quon","year":"2018","unstructured":"Quon H, Vapiwala N, Forastiere A, Kennedy EB. Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline Summary. J Oncol Pr. 2018;14:117\u201322.","journal-title":"J Oncol Pr"},{"key":"2912_CR42","volume":"12","author":"B Tawk","year":"2021","unstructured":"Tawk B, Debus J, Abdollahi A. Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer-Striking the Balance Between Toxicity and Cure. Front Pharm. 2021;12:753387.","journal-title":"Front Pharm"},{"key":"2912_CR43","volume":"229","author":"L Alessandrini","year":"2022","unstructured":"Alessandrini L, Zanoletti E, Cazzador D, Sbaraglia M, Franz L, Tealdo G, et al. Tumor budding to investigate local invasion, metastasis and prognosis in temporal bone squamous cell carcinoma. Pathol Res Pr. 2022;229:153719.","journal-title":"Pathol Res Pr"},{"key":"2912_CR44","doi-asserted-by":"crossref","first-page":"818","DOI":"10.5009\/gnl20224","volume":"15","author":"K Ichimasa","year":"2021","unstructured":"Ichimasa K, Kudo SE, Miyachi H, Kouyama Y, Misawa M, Mori Y. Risk Stratification of T1 Colorectal Cancer Metastasis to Lymph Nodes: Current Status and Perspective. Gut Liver. 2021;15:818\u201326.","journal-title":"Gut Liver"},{"key":"2912_CR45","doi-asserted-by":"publisher","unstructured":"Chiesa-Estomba CM, Thompson L, Agaimy A, Zidar N, Simpson RHW, Franchi A, et al. Predictive value of tumor budding in head and neck squamous cell carcinoma: an update. Virchows Arch. 2023; Available from: https:\/\/doi.org\/10.1007\/s00428-023-03630-6.","DOI":"10.1007\/s00428-023-03630-6"},{"key":"2912_CR46","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104670","volume":"105","author":"P Molony","year":"2020","unstructured":"Molony P, Werner R, Martin C, Callanan D, Nauta I, Heideman D, et al. The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma. Oral Oncol. 2020;105:104670.","journal-title":"Oral Oncol"},{"key":"2912_CR47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","volume":"24","author":"H Mehanna","year":"2023","unstructured":"Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24:239\u201351.","journal-title":"Lancet Oncol"},{"key":"2912_CR48","doi-asserted-by":"publisher","unstructured":"Economopoulou P, Kotsantis I, Psyrri A. De-Escalating Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma. Viruses. 2021;13. Available from: https:\/\/doi.org\/10.3390\/v13091787.","DOI":"10.3390\/v13091787"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02912-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02912-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02912-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T15:37:28Z","timestamp":1737387448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02912-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,10]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02912-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FS: No conflict of interest. MW: No conflict of interest. ML: Is a member of DKTK school of oncology and received funding from DKFZ Clinical Scientist Program (H70). BW: No conflict of interest. BS: No conflict of interest. CCH: No conflict of interest. IO: No conflict of interest. JH: No conflict of interest. ME: Research funding from the Else Kr\u00f6ner-Fresenius Foundation\/EKFS (2020_EKEA.129; 2023_EKES.07), the TOPeCS funding line of the IZKF (IZKF-FAU T04) of the FAU, an advanced research grant of the IZKF of the FAU Erlangen-N\u00fcrnberg (IZKF-FAU D41) and a Young Clinical Scientist Fellowship of the Bavarian Center for Cancer Research (BZKF; YSF-TP01). Declares Personal fees, travel costs and speaker\u2019s honoraria from MSD, AstraZeneca, Janssen-Cilag, Cepheid, Diaceutics; research funding from AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead; advisory roles for Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth and Gilead. AH: No conflict of interest. HI: No conflict of interest. AOG: No conflict of interest. MBa: No conflict of interest. MJ: No conflict of interest. JRI: Funding from University of Luebeck, Habilitation Grant (H01-2022). VWS: No conflict of interest. SP: No conflict of interest. KLB: No conflict of interest. MH: No conflict of interest. LL: No conflict of interest. CMSL:No conflict of interest. CR: No conflict of interest. CM: No conflict of interest. JB: Funding from Deutsche Krebshilfe (German Cancer Aid), Consulting: MSD. MBo: Funding from Deutsche Krebshilfe (German Cancer Aid), Else Kr\u00f6ner Fresenius Stiftung. Funding for Research: BMS. Advisory Boards and speakers\u2019 fees: BMS, MSD, Trillium Akademie","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The analyses were conducted with participants\u2019 consents and in accordance with the declaration of Helsinki. An ethics vote by the local ethics committees was obtained: Friedrich-Alexander University Erlangen- Nuremberg: 23- 22- Br, University of Heidelberg: S-680\/2021, University of L\u00fcbeck: AZ 16-277 and Technical University of Munich: 2023-543-S-SB. An ethics vote was not deemed necessary for the Christian-Albrechts-Universit\u00e4t zu Kiel due to the anonymized retrospective nature of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}